India's Agni long-range missiles broke UN limits, says China

January 5, 2017

Beijing, Jan 5,: India has "broken" UN limits on nuclear arms and long-range missiles and Pakistan should also be accorded the same "privilege", state-run Chinese media said today as it criticised New Delhi for carrying out Agni-4 and 5 missile tests whose range covers the Chinese mainland.

agni

"India has broken the UN's limits on its development of nuclear weapons and long-range ballistic missile," the ruling Communist Party-run tabloid Global Times said in its editorial.

"The US and some Western countries have also bent the rules on its nuclear plans. New Delhi is no longer satisfied with its nuclear capability and is seeking intercontinental ballistic missiles that can target anywhere in the world and then it can land on an equal footing with the UN Security Council's five permanent members," it said.

"India is 'promising' in vying for permanent membership on the UN Security Council as it is the sole candidate who has both nuclear capability and economic potential," it said.

"China should realise that Beijing wouldn't hold back India's development of long-range ballistic missiles," it said apparently highlighting China's limitations in restricting India developing a nuclear and missile deterrence against Chinese military power.

Agni-5, a 5,000-km range intercontinental ballistic missile (ICBM), is widely regarded as a strategic missile targeted at China as it can reach almost all parts of the Chinese mainland.

The editorial said that "Chinese don't feel India's development has posed any big threat to it".

The daily known for its sabre-rattling rhetoric said "India wouldn't be considered as China's main rival in the long run" due to vast disparity of in power between the two countries.

But at the same time it suggested that the "best choice for Beijing and New Delhi is to build rapport".

However, while accusing India of violating limits imposed by UN on nuclear and long range missile development, "if the Western countries accept India as a nuclear country and are indifferent to the nuclear race between India and Pakistan, China will not stand out and stick rigidly to those nuclear rules as necessary", it said.

"At this time, Pakistan should have those privileges in nuclear development that India has," it said, indicating that China which shared an all-weather ties with Islamabad will back it if it develops long-range missiles.

"In general, it is not difficult for India to produce intercontinental ballistic missiles which can cover the whole world. If the UN Security Council has no objection over this, let it be. The range of Pakistan's nuclear missiles will also see an increase. If the world can adapt to these, China should too," it said.

The references to violation of UN rules by the daily were significant as the Chinese Foreign Ministry spokesperson Hua Chunying while reacting to India's Agni-5 missile test said on December 27 that"on whether India can develop this ballistic missile that can carry nuclear weapons, I think relevant resolutions of the UNSC have clear rules".

Comments

Rikaz
 - 
Thursday, 5 Jan 2017

Good, China is scared of us.....

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 30,2020

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 20,2020

New Delhi, Jan 20: Surging inflation and slowing growth are raising serious concerns about the future growth prospects of the economy and as a remedial measure the government should resolve supply-side hurdles and ensure more stringent governance norms, a report said on Monday.

According to the Dun and Bradstreet Economy forecast, even though the Index of Industrial Production (IIP) turned positive in November 2019, it is likely to remain subdued.

"Slowdown in consumption and investment along with high inflationary pressures, geopolitical issues and uncertainty over the recovery of the economic growth are likely to keep IIP subdued," the report noted.

Dun and Bradstreet expect IIP to remain around 1.5-2.0 percent during December 2019.

As per government data, industrial output grew 1.8 percent in November, turning positive after three months of contraction, on account of growth in the manufacturing sector.

On the price front, uneven rainfall along with floods in many states and geopolitical issues have led to a surge in headline inflation even as demand remains muted.

The Consumer Price Index (CPI) in December rose to about five-and-half year high of 7.35 percent from 5.54 percent in November, mainly driven by high vegetable prices.

"The sharp rise in inflation has constrained monetary policy stimulus while revenue shortfall has placed limits on the government expenditure," Dun & Bradstreet India Chief Economist Arun Singh said.

According to Singh, growth-supporting measures and deceleration in growth are likely to cause slippage in fiscal deficit target by a wider margin.

"The government should focus on taking small steps to address the slowdown; in particular, resolve the supply-side hurdles and ensure more stringent governance norms," Singh said.

Unless these concerns are addressed through a comprehensive policy framework, it will not be easy for India to clock a sustainable growth rate to become a USD 5 trillion economy, he added.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 28,2020

New Delhi, Apr 28: Nafisa Ali took to Instagram to share the inspiring story of her niece, Diya Naidu, who donated her plasma to help patients suffering from Covid-19 after recovering from the disease. The veteran actress shared a photo of her niece from the hospital bed and asked fans to read Diya's post to get a detailed account of her experience.

Nafisa wrote, "Diya Naidu my niece - a COVID19 hero - is back home after donating her plasma - looks like liquid gold - it’s value is priceless as it will save lives. So please read her COVID19 story and share the information that is first hand. It is the need of the hour. Help save lives. #diyanise. #diyanaidu #covid_19 #india (sic)."

Diya Naidu, who is a dancer and choreographer based in Bengaluru, revealed in her Instagram post that she has donated her plasma for other Covid-19 patients. She said that the method has been super effective wherever it's been tried.

Earlier, Nafisa Ali gave a shout-out to her niece on Instagram and penned a heartfelt note for her. She wrote, "I am so grateful to you brave child - a COVID19 warrior (living in Bangalore) has agreed to donate her plasma to help cure other COVID19 serious patients (sic)."

Explaining the process of plasma therapy to treat Covid-19 patients, she wrote, "The process of donating plasma to treat COVID-19 is not very complex and can be done in just two hours. One of the most discussed methods of treatment of the disease caused by the novel coronavirus is plasma therapy, which involves the transfusion of plasma from a convalescent coronavirus patient to a critical patient. The blood of a recovering patient is rich in antibodies produced by the body to fight the virus, which are expected to help the critical patient recover (sic)."

Plasma therapy has been suggested to treat people suffering from Covid-19. People, who have recovered from the disease, are donating plasma as it contains antibodies to fight the disease. Earlier, Kanika Kapoor, who was the first Bollywood celebrity to be diagnosed with the disease, also offered to donate her plasma. She has recovered from Covid-19 and is currently living with her family in Lucknow.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.